汇宇制药：注射用环磷酰胺获英国上市许可

Core Insights - The company, Huayu Pharmaceutical, announced that its subsidiary, SEACROSS PHARMACEUTICALS LIMITED, has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency for its injectable cyclophosphamide product [1] - This drug is primarily used for the treatment of chronic lymphocytic leukemia (CLL) and various other diseases [1] - The injectable cyclophosphamide has already obtained marketing approvals in China, the UK, Ireland, Portugal, France, the Netherlands, Italy, and Spain, and a registration application has been submitted in Germany [1] - The approval in the UK is expected to enhance the company's product pipeline in international markets and improve its brand image [1]